Gossamer Bio, Inc. — Director's Dealing 2019

Feb 8, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2019-02-07

Reporting Person: Gujrathi Sheila (Director, President & CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3976212	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock (49596)		Indirect
Series B Preferred Stock	$0.00		Common Stock (12434)		Indirect

Footnotes

F1: Includes 2,595,584 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person.

F2: The 223,182 shares of Series A Preferred Stock held by a trust for the benefit of the Reporting Person's family are convertible, at any time, at the holder's election, at a ratio of 4.5 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's

F3: The 55,957 shares of Series B Preferred Stock held by a trust for the benefit of the Reporting Person's family are convertible, at any time, at the holder's election, at a ratio of 4.5 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert at a ratio of 4.5 to one share of the Issuer's common stock. The Series B Preferred Stock has no expiration date.